Of course, mutations in the TP53 gene have been shown as a mechanism of both primary and secondary resistance to MDM2 inhibitors (Jeay et al, 2015), but the molecular alterations underpinning the activity of other inhibitors of anti-apoptotic proteins in AML remains to be identified. This evidence concerns the gene TP53 and acute myeloid leukemia.